Covid-19 vaccine contest turns to T-cell responses
The coronavirus vaccine race now features three front runners with clinical data, and at least one boasts impressive T-cell responses.
Synairgen joins the 2020 coronavirus winners club
A small trial of inhaled interferon marks a 30-fold increase in Synairgen stock since January, but the endpoints warrant scrutiny.
Moderna's Covid-19 vaccine shows promise
But the trade-off between efficacy and tolerability could limit mRNA-1273’s use to those who need it least.
Tecentriq’s ovarian failure highlights a changing market
An Avastin combination draws a blank in the Imagyn-050 study. Will a combo with a Parp inhibitor fare any better?
Obseva shows why red flags are worth heeding
A crucial second pivotal trial in uterine fibroids fails to dispel concerns about the company’s linzagolix.
Idorsia claims second insomnia hit, but has it done enough?
Daridorexant can't reach the heights of its first pivotal study win, but a pooled analysis could still save it.
Bellus chokes in chronic cough
After Merck’s success with a P2X3 inhibitor hopes were high for Bellus’s similar compound. They are now dashed.
Covid-19 vaccines remain hot – in spite of Inovio
Biontech and Pfizer come roaring back with the first human data on BNT162, a day after Inovio’s effort disappointed.
Akero continues to pull ahead of Nash rivals
Biopsy data set up efruxifermin as a strong contender in the race to find an effective Nash treatment.
